■論説
がん医療と緩和ケア（6）―抗がん剤の薬物動態と薬力学について〜エルロチニブを例として〜
鈴木 藍, 伊勢 雄也, 片山 志郎
日本医科大学付属病院薬剤部
Treatment of Cancer and Palliative Care (6) Pharmacokinetics and Pharmacodynamics of Antineoplastic Agents
Ai Suzuki, Yuya Ise and Shirou Katayama
Department of Pharmaceutical Service, Nippon Medical School Hospital
Basic research has produced a wealth of knowledge regarding the molecular mechanisms of cancer development, and antineoplastic agents that target specific molecules have been developed. These agents have the potential to revolutionize cancer management in terms of the risk/benefit ratio of treatment.
This review article provides general concepts of pharmacokinetics and pharmacodynamics data of molecularly targeted agents, e.g. erlotinib. Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that has been used to treat nonsmall cell lung cancer and pancreatic cancer.
日医大医会誌 2015; 11(1), 12-15
Key words
pharmacokinetics, pharmacodynamics, antineoplastic agents, erlotinib
Correspondence to
Ai Suzuki, Department of Pharmaceutical Service, Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyou-ku, Tokyo 113-8603, Japan
E-mail：ai-s@nms.ac.jp
受付：2014年9月17日 受理：2014年11月12日 |
全文PDF